Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
1997 1
1998 3
1999 1
2001 3
2002 2
2003 1
2004 1
2005 2
2006 5
2007 2
2008 3
2009 2
2010 8
2011 11
2012 7
2013 6
2014 9
2015 6
2016 6
2017 8
2018 5
2019 6
2020 11
2021 11
2022 5
2023 9
2024 8
2025 11
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.
Mishra A, Abelman RO, Cunneely Q, Putaturo V, Deshpande AA, Bell R, Seider EM, Xu KH, Shan M, Kelly J, Huang SB, Rieur O, Knape J, Gopinathan KA, Kikkeri K, Edd JF, Walsh J, Dai CS, Ellisen LW, Ting DT, Nieman L, Toner M, Bardia A, Haber DA, Maheswaran S. Mishra A, et al. Among authors: ellisen lw. Proc Natl Acad Sci U S A. 2026 Jun 23;123(25):e2601563123. doi: 10.1073/pnas.2601563123. Epub 2026 Jun 17. Proc Natl Acad Sci U S A. 2026. PMID: 42308036 Free PMC article.
Sensitive detection of somatic mutations in GC-rich cancer gene promoters.
Qi M, Dave PS, Francis N, DeFelice M, Pollock S, Corbitt H, Mitsiades IR, Wang G, Frere P, Fox A, Khitrov G, Petersen C, Larkin K, Hamilton S, Ellisen LW, Gulhan DC, Hidalgo-Miranda A, Lennon N, Cibulskis C, Rheinbay E. Qi M, et al. Among authors: ellisen lw. NAR Cancer. 2026 May 4;8(2):zcag011. doi: 10.1093/narcan/zcag011. eCollection 2026 Jun. NAR Cancer. 2026. PMID: 42088607 Free PMC article.
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.
Wander SA, Lloyd MR, Keenan JC, Scott EC, Niemierko A, Spring LM, Fell GG, Shin J, Isakoff SJ, Moy B, Ryan L, Padden S, Fisher E, Newton A, Habin KR, Viscosi-Spieler ET, Scarpetti L, Varkaris A, Ellisen LW, Dubash T, Che D, Patel PS, de la Cruz FF, Sutaria DS, Sane RS, Micalizzi DS, Maheswaran S, Haber DA, Juric D, Bardia A. Wander SA, et al. Among authors: ellisen lw. Lancet Oncol. 2026 May;27(5):580-591. doi: 10.1016/S1470-2045(26)00059-8. Lancet Oncol. 2026. PMID: 42061370 Clinical Trial.
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.
Wu B, Thant W, Bitman E, Liu T, Liu J, Paschalis EI, Patel BK, Nawrocki C, Xu KH, Nieman LT, Ting DT, de Gois Macedo B, Cheng Y, Jiang K, Sun F, Thimmiah N, Sun S, Abelman RO, Bossuyt VI, Isakoff SJ, Spring LM, Bardia A, Ellisen LW. Wu B, et al. Among authors: ellisen lw. J Immunother Cancer. 2026 Apr 3;14(4):e012265. doi: 10.1136/jitc-2025-012265. J Immunother Cancer. 2026. PMID: 41932810 Free PMC article.
Current landscape of sequencing ADCs in metastatic breast cancer.
McLaughlin S, Ravani LV, Moy B, Medford AJ, Isakoff SJ, Liu T, Ellisen LW, Spring LM, Wander SA, Abelman RO. McLaughlin S, et al. Among authors: ellisen lw. Ther Adv Med Oncol. 2025 Dec 17;17:17588359251396656. doi: 10.1177/17588359251396656. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 41424607 Free PMC article. Review.
Selection biases in the systematic collection of breast biobank specimens.
Bar Y, Wang GX, Gioia GE, Fell G, Chou SS, Bossuyt V, Isakoff SJ, Moy B, Ellisen LW, Lehman CD, Spring LM. Bar Y, et al. Among authors: ellisen lw. NPJ Breast Cancer. 2025 Aug 1;11(1):83. doi: 10.1038/s41523-025-00798-9. NPJ Breast Cancer. 2025. PMID: 40750597 Free PMC article.
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.
Lloyd MR, Chica-Parrado R, Weipert CM, Knepper TC, Podany EL, Napolitano F, Ye D, Lin CC, Uemoto Y, Liao J, Wegrzyn C, Walko CM, Ryan LY, Keenan JC, Medford AJ, Liu SA, Wulf GM, Clifton KK, Ma CX, Han HS, Zhang N, Ellisen LW, Bardia A, Arteaga CL, Hanker AB, Wander SA. Lloyd MR, et al. Among authors: ellisen lw. EBioMedicine. 2025 Aug;118:105828. doi: 10.1016/j.ebiom.2025.105828. Epub 2025 Jun 27. EBioMedicine. 2025. PMID: 40578027 Free PMC article.
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski LA, Spring LM, Ellisen LW, Doebele RC, Cristofanilli M, Getz G, Bardia A. Medford AJ, et al. Among authors: ellisen lw. Breast Cancer Res Treat. 2025 Aug;212(3):437-447. doi: 10.1007/s10549-025-07710-w. Epub 2025 May 29. Breast Cancer Res Treat. 2025. PMID: 40439821 Free PMC article.
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, Bitman E, Thant W, Liu T, Weipert C, Fell G, Spring LM, Wander SA, Moy B, Vidula N, Isakoff SJ, Varkaris A, Juric D, Corcoran RB, Ellisen LW, Bardia A. Abelman RO, et al. Among authors: ellisen lw. Clin Cancer Res. 2025 May 15;31(10):1966-1974. doi: 10.1158/1078-0432.CCR-24-2771. Clin Cancer Res. 2025. PMID: 39745368 Free PMC article.
148 results